Which drug best prevents bone loss after stopping osteoporosis treatment?
NCT ID NCT07406685
First seen Feb 14, 2026 · Last updated Apr 29, 2026 · Updated 13 times
Summary
This study tests whether a bone-strengthening drug called ibandronate works as well as another drug, zoledronic acid, to prevent bone loss in postmenopausal women who have stopped taking denosumab. About 52 women aged 50-85 with osteoporosis or low bone density will receive one of the two drugs and have their bone density monitored for 24 months. The goal is to find a safe way to maintain bone health after stopping denosumab.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Taiwan University Hospital
Taipei, 100, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.